base-metals-investing Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
base-metals-investing FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
base-metals-investing Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
base-metals-investing Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
base-metals-investing Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
base-metals-investing Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
base-metals-investing Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
base-metals-investing Ryoncil® Receives J-Code From Medicare & Medicaid Services Facilitating Reimbursement and Broader Patient Access
Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award
U.S. Army Awards Salesforce $5.6B Contract to Accelerate Military Modernization and Department of War Readiness
American Pacific Mails Meeting Materials for Annual General and Special Meeting in Connection with Previously Announced Plan of Arrangement with ICG Silver & Gold Ltd.
